BMY
Stock Details
BMY is Bristol-Myers Squibb Company's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 68.13$. Average daily volumn in 3 months 7.98M. Market cap 135.38B
Stock symbol : BMY. Exchange : NYSE. Currency : USD Lastest price : 64.44$. Total volume : 5.64M. Market state POST Click reload if you want to check the lastest price on market!!!
Bristol-Myers Squibb Company (BMY)
Last Price
64.44$Change
0.73Volume
5.64M
| Previous Close | 63.71 |
| Open | 63.69 |
| Day Range | 63.17-64.60 |
| Bid | 0.00 x 1.1k |
| Ask | 0.00 x 800 |
| Volume | 5.64M |
| Average Volume | 7.98M |
| Market Cap | 135.38B |
| Beta | 0.43 |
| 52 Week Range | 63.07-81.44 |
| Trailing P/E | 18.79 |
| Foward P/E | 7.92 |
| Dividend (Yield %) | 3.58% |
| Ex-Dividend Date | 2023-04-06 |
Financial Details
Organization
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myelom... a; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Market Cap:
135.38BRevenue:
46.16BTotal Assets:
96.82BTotal Cash:
9.12B
News about "Bristol-Myers Squibb Company"
BMY Bristol-Myers Squibb Company
Source from : Seeking Alpha - 6 days ago
**NM signifies a non meaningful value. A dash signifies the data is not available.See details»
Bristol-Myers Squibb Company (BMY): Today's Featured Drugs Winner
Source from : TheStreet.com - 12 days ago
Bristol-Myers Squibb Company was a winner within the drugs industry, rising 85 cents (2.6%) to $33.94 on heavy volume. Bristol-Myers Squibb Company was a winner within the drugs industry ...See details»
The Stock Of Bristol-Myers Squibb Company (NYSE: BMY) Is Forecast To Pass $92.00 In A Year
Source from : stocksregister - 7 days ago
The trading price of Bristol-Myers Squibb Company (NYSE:BMY) closed higher on Tuesday, May 23, closing at $66.53, 1.09% higher than its previous close. Traders who pay close attention to intraday ...See details»
Bristol-Myers Squibb Company (BMY) Stock: Evaluating the Market Performance
Source from : newsheater - 9 days ago
The price-to-earnings ratio for Bristol-Myers Squibb Company (NYSE: BMY) is 19.18x, which is above its average ratio. Moreover, the 36-month beta value for BMY is 0.43. Analysts have varying opinions ...See details»
Bristol-Myers Squibb Company (BMY) Shares Plummet Below 1-Year High
Source from : newsheater - 16 days ago
Bristol-Myers Squibb Company (NYSE: BMY)’s stock price has plunge by -1.59relation to previous closing price of 66.53. Nevertheless, the company has seen a -1.59% plunge in its stock price over the ...See details»
Bristol-Myers Squibb Company (BMY): Today's Featured Health Care Laggard
Source from : TheStreet.com - 1 month ago
Bristol-Myers Squibb Company was a leading decliner within the health care sector, falling 50 cents (-1.5%) to $32.12 on light volume. Bristol-Myers Squibb Company was a leading decliner within ...See details»
Latest news for Bristol-Myers Squibb
Source from : Fortune - 19 days ago
Newsletters What a Bristol-Myers project to monitor off-label prescribing says about future uses of A.I. © 2023 Fortune Media IP Limited. All Rights Reserved. Use of ...See details»
Data-Based Insights About Bristol-Myers Squibb Company (BMY)
Source from : stocksregister - 6 month ago
Bristol-Myers Squibb Company (NYSE:BMY) price on Thursday, May 18, fall -1.25% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $65.70. A look at the stock ...See details»
Bristol-Myers Squibb Company (NYSE:BMY) insiders sold US$35m worth of stock suggesting impending weakness.
Source from : Yahoo News UK - 1 month ago
Many Bristol-Myers Squibb Company (NYSE:BMY) insiders ditched their stock over the past year, which may be of interest to the company's shareholders. When analyzing insider transactions, it is usually ...See details»
In the wake of Bristol-Myers Squibb Company's (NYSE:BMY) latest US$8.0b market cap drop, institutional owners may be forced to take severe actions
Source from : Yahoo Finance - 1 month ago
Bristol-Myers Squibb already has institutions on the share registry. Indeed, they own a respectable stake in the company. This can indicate that the company has a certain degree of credibility in the ...See details»
A Closer Look At Bristol-Myers Squibb Company's (NYSE:BMY) Impressive ROE
Source from : Yahoo Finance - 16 days ago
To keep the lesson grounded in practicality, we'll use ROE to better understand Bristol-Myers Squibb Company (NYSE:BMY). ROE or return on equity is a useful tool to assess how effectively a company ...See details»
How Did Bristol-Myers Squibb Company's (NYSE:BMY) 20% ROE Fare Against The Industry?
Source from : Yahoo Movies UK - 1 month ago
To keep the lesson grounded in practicality, we'll use ROE to better understand Bristol-Myers Squibb Company (NYSE:BMY). Return on equity or ROE is a key measure used to assess how efficiently a ...See details»
Bristol-Myers Squibb Company Common Stock (BMY)
Source from : Nasdaq - 5 years ago
Get up to 10 years of daily historical stock prices & volumes. The "Close/Last" is the “adjust consolidated close price”. Data provided by Edgar Online. The net and percent change in the ...See details»
In the wake of Bristol-Myers Squibb Company's (NYSE:BMY) latest US$8.0b market cap drop, institutional owners may be forced to take severe actions
Source from : Yahoo Movies UK - 1 month ago
Bristol-Myers Squibb already has institutions on the share registry. Indeed, they own a respectable stake in the company. This can indicate that the company has a certain degree of credibility in the ...See details»